# APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

> **NCT02706353** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 34 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** APX005M
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02706353
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-02
- **Primary completion:** 2025-03-10
- **Final completion:** 2025-03-10
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** \<75% participant accrual
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02706353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02706353, "APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02706353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*